Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
1.
J Ovarian Res ; 13(1): 22, 2020 Feb 26.
Article in English | MEDLINE | ID: mdl-32101156

ABSTRACT

BACKGROUND: Fragile X premutation (Amplification of CGG number 55-200) is associated with increased risk for fragile X-Associated Premature Ovarian Insufficiency (FXPOI) in females and fragile X-associated tremor/ataxia syndrome (FXTAS) predominantly in males. Recently, it has been shown that CGG repeats trigger repeat associated non-AUG initiated translation (RAN) of a cryptic polyglycine-containing protein, FMRpolyG. This protein accumulates in ubiquitin-positive inclusions in neuronal brain cells of FXTAS patients and may lead to protein-mediated neurodegeneration. FMRpolyG inclusions were also found in ovary stromal cells of a FXPOI patient. The role of FMRpolyG expression has not been thoroughly examined in folliculogenesis related cells. The main goal of this study is to evaluate whether FMRpolyG accumulates in mural granulosa cells of FMR1 premutation carriers. Following FMRpolyG detection, we aim to examine premutation transfected COV434 as a suitable model used to identify RAN translation functions in FXPOI pathogenesis. RESULTS: FMRpolyG and ubiquitin immunostained mural granulosa cells from six FMR1 premutation carriers demonstrated FMRpolyG aggregates. However, co-localization of FMRpolyG and ubiquitin appeared to vary within the FMR1 premutation carriers' group as three exhibited partial ubiquitin and FMRpolyG double staining and three premutation carriers demonstrated FMRpolyG single staining. None of the granulosa cells from the five control women expressed FMRpolyG. Additionally, human ovarian granulosa tumor, COV434, were transfected with two plasmids; both expressing 99CGG repeats but only one enables FMRpolyG expression. Like in granulosa cells from FMR1 premutation carriers, FMRpolyG aggregates were found only in COV434 transfected with expended CGG repeats and the ability to express FMRpolyG. CONCLUSIONS: Corresponding with previous studies in FXTAS, we demonstrated accumulation of FMRpolyG in mural granulosa cells of FMR1 premutation carriers. We also suggest that following further investigation, the premutation transfected COV434 might be an appropriate model for RAN translation studies. Detecting FMRpolyG accumulation in folliculogenesis related cells supports previous observations and imply a possible common protein-mediated toxic mechanism for both FXPOI and FXTAS.


Subject(s)
Fragile X Mental Retardation Protein/genetics , Fragile X Mental Retardation Protein/metabolism , Granulosa Cells/metabolism , Adult , Animals , Ataxia/genetics , Ataxia/metabolism , Disease Models, Animal , Female , Fragile X Syndrome/genetics , Fragile X Syndrome/metabolism , Humans , Mice , Mice, Transgenic , Mutation , Primary Ovarian Insufficiency/genetics , Primary Ovarian Insufficiency/metabolism , Transfection , Tremor/genetics , Tremor/metabolism
2.
Reprod Biomed Online ; 22(3): 257-62, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21269881

ABSTRACT

The aim of this study was to identify the size in which the dominant follicle acquires the ability to produce a functional corpus luteum. This observational study includes 15 women with ovulatory cycles who underwent human chorionic gonadotrophin (HCG)-primed in-vitro maturation (IVM) treatments without embryo transfer. All patients received subcutaneous injection of HCG 10,000 IU 38 h prior to oocyte retrieval. Five to seven days following retrieval, serum concentrations of progesterone and oestradiol were measured along with ultrasound scan measuring the antral follicle count. Using receiver operating characteristic curves and the Youden index (J), this study clearly shows that the diameter of the dominant follicle at the time of the LH surge is a good predictor for its ability to form a progesterone-producing corpus luteum (area under the curve 0.94). These findings revealed that the dominant follicle develops the competence to form a corpus luteum, signified by the production of more than 10 nmol/l serum progesterone at 5-7 days from oocyte retrieval, as soon as it acquires a diameter of 10.5-12.0mm. In addition, a new cohort of viable antral follicles can be identified as early as 5-7 days following IVM oocyte retrieval.


Subject(s)
Cell Size , Chorionic Gonadotropin/pharmacology , Models, Biological , Ovarian Follicle/cytology , Reproductive Techniques, Assisted , Adult , Area Under Curve , Chorionic Gonadotropin/administration & dosage , Corpus Luteum/cytology , Estradiol/blood , Female , Humans , In Vitro Techniques , Ovarian Follicle/drug effects , Progesterone/blood , ROC Curve , Statistics, Nonparametric
3.
Reprod Biomed Online ; 19(6): 778-83, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20031016

ABSTRACT

The aim of this study was to evaluate the affect of age at the time of orchidopexy on testicular sperm extraction (TESE) results among patients with a history of cryptorchidism and azoospermia. This retrospective study compared TESE results for couples undergoing IVF treatment, among two groups of patients. Group A included patients who underwent orchidopexy at age 10 and younger, and group B included patients who had the procedure above the age of 10. A total of 42 patients were included in the study. Forty patients had bilateral cryptorchidism and two had unilateral. The overall rate of sperm recovery was 59.5%. No differences were found in the sperm retrieval, fertilization, implantation, pregnancy, or live birth rates between the groups. The results suggest that age at orchidopexy, either at 10 years of age or younger or above 10 years of age, was not a predictive factor for successful TESE. Although bilateral cryptorchidism is usually considered a testicular secretory dysfunction, it was found that sperm retrieval attempts yielded spermatozoa in almost 60% of patients with azoospermia and a history of cryptorchidism.


Subject(s)
Cryptorchidism/surgery , Orchiopexy/methods , Sperm Retrieval , Testis/surgery , Adult , Age Factors , Azoospermia/etiology , Azoospermia/surgery , Biopsy , Child , Child, Preschool , Cryptorchidism/complications , Female , Fertilization in Vitro , Follicle Stimulating Hormone/blood , Humans , Infant , Infertility, Male/etiology , Male , Organ Size , Pregnancy , Pregnancy Outcome , Retrospective Studies , Testis/anatomy & histology
4.
Rheumatology (Oxford) ; 47(10): 1506-9, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18660508

ABSTRACT

OBJECTIVE: To describe a case series of seven women with SLE and other systemic autoimmune rheumatic diseases (SARDs) who required cyclophosphamide therapy and underwent fertility preservation treatments. METHODS: Of the seven patients reported here, five women had SLE with nephritis, the sixth had immune thrombocytopenia purpura (ITP) and the seventh had microscopic polyangiitis (MPA) with renal involvement. All women were nulliparous and younger than 35 yrs. RESULTS: Patients with SLE underwent in vitro maturation (IVM) of immature oocytes aspirated during a natural menstrual cycle followed by vitrification of the matured oocytes if a male partner was not available, or vitrification of embryos if one was available. The patient with ITP and the patient with MPA underwent gonadotropin ovarian stimulation followed by oocyte or embryo vitrification. All women completed fertility preservation treatment successfully and mature oocytes or embryos (36 and 13, respectively) were vitrified. No complications were associated with this treatment and cytotoxic therapy was initiated as scheduled in all cases. CONCLUSIONS: Oocyte or embryo cryopreservation should be considered for fertility preservation in young women with SARDs who face imminent gonadotoxic treatment. In patients, where gonadotropin ovarian stimulation is deemed unsafe, IVM of immature oocytes, aspirated during a natural menstrual cycle, followed by vitrification or fertilization of the mature oocytes, seems to be safe and feasible. For patients in whom hormonal ovarian stimulation is not contraindicated, this method may be considered depending on the urgency to start cytotoxic therapy.


Subject(s)
Autoimmune Diseases/drug therapy , Cryopreservation/methods , Cyclophosphamide/adverse effects , Immunosuppressive Agents/adverse effects , Infertility, Female/prevention & control , Adult , Cyclophosphamide/therapeutic use , Embryo, Mammalian , Female , Fertility , Humans , Immunosuppressive Agents/therapeutic use , Infertility, Female/chemically induced , Lupus Nephritis/drug therapy , Oocyte Retrieval/methods , Oocytes , Ovulation Induction/methods
5.
Reprod Biomed Online ; 12(4): 418-22, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16740213

ABSTRACT

Adequate ovarian response, essential for successful IVF, cannot be accurately predicted. This study retrospectively reviewed all patients undergoing IVF from 1998 to 2001. Inclusion criteria were age <41 years at treatment onset and a basal day 3 serum FSH concentration <12 IU/l. Women with FSH or=3 in group 1 and <3 in group 2 (controls). Age at treatment initiation, basal serum day 3 FSH and LH concentrations, peak serum oestradiol concentration, number of retrieved and fertilized oocytes and pregnancy rate were analysed. Groups 1 (n = 41, 111 IVF treatment cycles) and 2 (n = 596, 1,434 IVF treatment cycles) were similar in term of woman's mean age. Group 1 had significantly higher mean basal day 3 FSH concentration (P < 0.01) and significantly lower oestradiol concentrations at oocyte retrieval (P < 0.01), mean number of oocytes retrieved and fertilized (P < 0.01) and pregnancy rate (P = 0.016). The same trend persisted after excluding 98 patients with basal FSH concentrations >8 IU/l. In conclusion, elevated day 3 FSH/LH ratio is associated with an inferior outcome in IVF treatment cycles and may be used as an additional predictor for decreased ovarian response.


Subject(s)
Follicle Stimulating Hormone/blood , Infertility, Female/therapy , Luteinizing Hormone/blood , Ovulation Induction/methods , Pregnancy Rate , Adult , Biomarkers/blood , Cohort Studies , Estradiol/blood , Female , Humans , Infertility, Female/blood , Predictive Value of Tests , Pregnancy , Retrospective Studies , Treatment Outcome
6.
Harefuah ; 143(8): 580-4, 622, 2004 Aug.
Article in Hebrew | MEDLINE | ID: mdl-15523811

ABSTRACT

P-450 aromatase inhibitors, designed for suppressing estradiol production, were first approved for the treatment of advanced breast cancer. Recent studies have provided evidence that aromatase inhibitors may be effective in the short term for induction of ovulation and in the long-term for treatment of endometriosis. Based on current data, the role of aromatase inhibitors in the management of various gynecological conditions may soon be widely determined.


Subject(s)
Aromatase Inhibitors/therapeutic use , Genital Diseases, Female/drug therapy , Endometriosis/drug therapy , Estrogen Antagonists/therapeutic use , Female , Humans , Ovulation Induction
7.
Am J Perinatol ; 18(8): 427-32, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11733857

ABSTRACT

The objective of this paper is to examine the outcome of pregnancies with extreme weight-discordant twins. Percentage of birth weight discordancy was defined as the birth weight difference between the twins divided by the larger twin's weight and multiplied by 100. Discordancy was calculated for all twin births in which both fetuses were live born. In 33 pairs, the discordancy was defined as extreme (>35%) and they constituted the study group. Thirty-three pairs of twin defined with mild weight discordancy (15-25%), and 33 pairs defined as concordant to birth weight (<15% difference) were matched to the study group patients based on gestational age at delivery (+/- 7 days) and on the mode of delivery, and constituted the control groups. The records of all the patients were reviewed for pregnancy complications and for major and minor neonatal outcome variables. Significantly more parturients in the study groups were primiparous undergoing in vitro fertilization treatments to conceive. Significantly more women in the study group had severe preeclampsia compared with women with mild discordancy or concordant twins (12.1 vs. 3.0% and 0%, respectively, p <0.025). No significant differences were encountered between the groups in neonatal mortality or morbidity factors except an increased rate of hyperbilirubinemia in the study group, p = 0.006. Using logistic regression analysis, discordancy was not defined as an efficient predictor for adverse neonatal outcome. Twin pregnancies with extreme discordancy have a favorable neonatal outcome in correlation with gestational age and not with the percentage of discordancy.


Subject(s)
Birth Weight , Pregnancy Outcome , Pregnancy, Multiple , Apgar Score , Female , Gestational Age , Humans , Logistic Models , Pregnancy , Retrospective Studies , Risk Factors , Twins
SELECTION OF CITATIONS
SEARCH DETAIL
...